Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-002 in Chinese Adults With Advanced Solid Tumors
NCT06238687Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of luveltamab tazevibulin in ovarian cancer, endometrial cancer (EC), non-small cell lung cancer (NSCLC) and 2 more (8 cohorts), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 5 more. Started Nov 2023; status: completed.
02
Drugs
luveltamab tazevibulin
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT06238687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238687.